Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Novel transcript, antisense to HERC1 is a long non-coding RNA (lncRNA) transcribed from the strand opposite to the HERC1 gene locus. As an antisense transcript, it likely plays a regulatory role in gene expression, potentially modulating the transcription, splicing, or stability of the HERC1 sense mRNA through various mechanisms, including chromatin remodeling, transcriptional interference, or RNAi pathways[2][6]. However, this transcript does not code for a protein product, is not considered a classical biological target for drug development, and its specific biological roles remain uncharacterized. There are currently no known drugs or biomarkers associated with this molecule, and its disease relevance has not been established in the literature.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to HERC1 (ENSG00000259589).